RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Using the CerviPrep™ drug delivery device to apply topical gemcitabine to the cervix may be
an effective way to kill more tumor cells.
PURPOSE: This phase II trial is studying how well CerviPrep™ works in applying topical
gemcitabine to the cervix in treating patients with primary endometrial cancer, cervical
cancer, or ovarian epithelial cancer.
- To evaluate the efficacy of the CerviPrep™ device in delivering topical gemcitabine
hydrochloride to the cervix
- To document any side effects directly attributed to local administration of gemcitabine
OUTLINE: Patients undergo application of topical gemcitabine hydrochloride directly to the
cervix using the CerviPrep™ drug delivery device during routine hysterectomy.
Uterine vein and peripheral blood samples are obtained periodically to measure local and
peripheral gemcitabine hydrochloride concentration levels in the blood. Local gemcitabine
hydrochloride concentration levels are also measured in uterine tissue samples obtained from
the surgical specimen after hysterectomy.
Patients complete a self-reported symptom diary for the first 7 days after surgery for
assessment of local and systemic side effects associated with topical administration of
After completion of study therapy, patients are followed at 2-4 weeks.
- Diagnosis of primary endometrial or cervical cancer
- Scheduled to undergo abdominal hysterectomy as part of surgical staging and/or
- Gynecologic Oncology Group (GOG) performance status 0-2
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
- Platelet count ≥ 100,000 cells/mm³
- Creatinine ≤ 2.5 mg/dL
- Serum Aspartate aminotransferase (AST) or Alanine transaminase (ALT) ≤ 3 times upper
limit of normal
- Total bilirubin ≤ 2.0 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Serious medical condition or psychiatric illness that places the patient at an
unacceptable risk for study participation or precludes signing the informed consent
- Known allergic reaction or hypersensitivity to gemcitabine hydrochloride
- Prior radiotherapy to the whole abdomen or pelvis
- More than 28 days since prior standard or experimental anticancer therapy
- No other concurrent anticancer agents